Several medical device companies took hits yesterday after analysts on Wall Street downgraded their stocks, on a day when the major market indices each closed up a hair, and even medtech firms that enjoyed upgrades came under pressure.
Globus Medical (NYSE:GMED) suffered the most after Morgan Stanley analyst David Lewis cut his rating on the stock from “overweight” to “equal-weight,” sliding -8.5% to a $39.61-per-share close yesterday, compared with the prior day’s closing price.
In fact, Lewis’s downgrades led the pack in terms of impact, taking Insulet (NSDQ:PODD) and Hologic (NSDQ:HOLX) shares down some -7.4% and -6.5%, respectively. Here’s a look at some of yesterday’s downgrade action:
|Company||Analyst||Old rating||New rating||Close 1/2/19||%|
|Globus (GMED)||Morgan Stanley||Overweight||Equal-Weight||$39.61||-8.5%|
|Insulet (PODD)||Morgan Stanley||Hold||Hold*||$73.43||-7.4%|
|Hologic (HOLX)||Morgan Stanley||Equal-Weight||Under-Weight||$38.42||-6.5%|
|Henry Schein (HSIC)||Robert W. Baird||Outperform||Neutral||$76.39||-2.7%|
|Smith & Nephew (SNN)||JP Morgan||Overweight||Neutral||$36.40||-2.6%|
|Bayer (BAYN)||JP Morgan||Overweight||Neutral||$17.40||-1.0%|
|*cut price target|
|Company||Analyst||Old rating||New rating||Close 1/2/2019||%|
|Tactile Systems (TCMD)||Northland Capital||Under Perform||Market Perform||$44.59||-2.1%|
|Stryker (SYK)||Evercore ISI||In-line||Outperform||$154.50||-1.4%|
|Zimmer Biomet (ZBH)||Citigroup||Neutral||Buy||$102.28||-1.4%|
|Bausch Health (BHC)||Piper Jaffray||Neutral||Overweight||$20.23||0.1%|
|Baxter (BAX)||Morgan Stanley||Under-Weight||Overweight||$65.30||0.8%|
|Apollo Endosurgery (APEN)||Northland Capital||Under Perform||Market Perform||$3.65||5.8%|
By way of comparison, the three major U.S. market indices all closed up a hair yesterday, with the Dow Jones Industrial Average closing up 0.1% at 23,346.24. The S&P 500 also closed up 0.1%, at 2,510.03, and the NASDAQ index ended at 6,665.94, up 0.5%.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.